A dermatological antipruritic device for clinical use

By designing easy-tear part one and easy-tear part two structures and air vents in the dermatology clinical anti-itch device, and by optimizing the materials of the breathable layer, drug isolation layer and adhesive layer, the problems of the device being difficult to tear and having poor breathability have been solved. This has resulted in convenient use and high breathability, making it suitable for long-term application and improving the practicality and safety of the device.

CN224975353UActive Publication Date: 2026-11-17920TH HOSPITAL OF THE JOINT LOGISTIC SUPPORT FORCE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202521991343.9
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2025-09-16
Publication Date
2026-11-17
Estimated Expiration
2035-09-16

AI Technical Summary

Technical Problem

Current dermatological antipruritic devices do not have an easy-tear release film structure, making them difficult to tear during use. They also lack a breathable structure, causing sweat to accumulate and leading to stuffiness, redness, swelling, and increased itching. Their poor breathability makes them impractical.

Method used

The release film is designed with two easy-tear sections for easy tearing, making it easy to tear. The anti-itch patch has breathable holes and uses a breathable layer, a drug isolation layer, an adhesive layer, and a release film, which are made of mesh non-woven fabric, cellulose nanofiber, silicone pressure-sensitive adhesive, and polyethylene material, respectively, to improve breathability and adhesion.

Benefits of technology

It facilitates the tearing of the release film, prevents sweat buildup, reduces skin stuffiness and itching, enhances breathability, is suitable for long-term use, improves ease of use and safety, and extends the product's shelf life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN224975353U_ABST
    Figure CN224975353U_ABST
Patent Text Reader

Abstract

This utility model relates to the field of dermatology technology and discloses a clinical anti-itch device for dermatology, including an anti-itch patch and a release film. The release film has a first easy-tear portion fixedly installed on its outer edge, and the anti-itch patch has a second easy-tear portion fixedly installed on its outer edge. The side of the anti-itch patch away from the release film has ventilation holes. The anti-itch patch includes a breathable layer, and a drug-resistant layer is adhered to the side of the breathable layer closest to the release film. A drug-resistant layer is disposed on the side of the drug-resistant layer closest to the release film. This clinical anti-itch device for dermatology, through the design of the first and second easy-tear portions, makes it easy for users to tear the release film during use, saving operation time and increasing practicality. The ventilation holes prevent sweat from accumulating between the anti-itch patch and the skin, reducing the probability of redness, swelling, and increased itching due to heat and stuffiness. It is especially suitable for long-term use. The multiple ventilation holes further improve overall breathability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This utility model relates to the field of dermatology technology, specifically to an antipruritic device for clinical use in dermatology. Background Technology

[0002] Clinical dermatological anti-itch devices are topical patch-type medical aids designed to relieve itchy skin symptoms. They are suitable for localized itching caused by eczema, contact dermatitis, insect bite dermatitis, xerosis, etc. Their core function is to quickly relieve itching through sustained-release medication or physical action, while preventing scratching that could lead to skin damage, infection, or worsening of the condition. They are mainly divided into two types: medicated and physical. Medicated patches often contain ingredients such as menthol, camphor, and weak corticosteroids (e.g., desonide), which inhibit the transmission of itch sensations at nerve endings and reduce local inflammation through skin penetration. Physical patches rely on breathable, hydrophilic materials to adhere to the skin, forming a protective film to reduce external irritation, or interfering with itch signals through a slightly cooling sensation. The size of these patches should be selected under the guidance of a medical professional based on the location and area of ​​the lesion. They are convenient to use, act locally, and are highly safe, making them a commonly used auxiliary tool for relieving localized itching in dermatology clinics and home care.

[0003] Chinese Utility Model Patent Publication No. CN212788878U discloses a skin anti-itch patch. The patch, as described in the specification, utilizes a multi-layered permeable membrane. Anti-itch medication is filled between the fixed membrane and the permeable membrane, as well as between adjacent permeable membranes, creating a concentration gradient for the medication and achieving a sustained-release effect. This facilitates absorption by the itchy area and maximizes the therapeutic effect. This novel anti-itch patch significantly improves the anti-itch effect, providing long-lasting relief for over 24 hours. It also prevents scratching of the itchy area, avoiding secondary infections caused by skin damage and reducing the risk of scarring. While convenient to use, this patch lacks an easy-tear release membrane structure, making it difficult to tear during use. Furthermore, it lacks a breathable structure, allowing sweat to easily accumulate between the patch and the skin, increasing the likelihood of redness, swelling, and aggravated itching due to heat and stuffiness. Its poor breathability and practicality limit its widespread use. Summary of the Invention

[0004] The technical problem to be solved by this utility model is to provide an anti-itch device for clinical use in dermatology. It can effectively solve the problems of existing technologies, such as the lack of an easy-tear structure for the release film, which makes it difficult to tear the release film during use, and the lack of a breathable structure, which makes it easy for sweat to accumulate between the anti-itch patch and the skin, increasing the probability of redness, swelling and itching due to stuffiness. It also has poor breathability, poor practicality and is not convenient for widespread use.

[0005] The technical solution adopted by this utility model is: a dermatological clinical anti-itch device, including an anti-itch patch and a release film, wherein an easy-tear part one is fixedly installed on the outer edge of the release film, an easy-tear part two is fixedly installed on the outer edge of the anti-itch patch, and a vent is provided on the side of the anti-itch patch away from the release film. The anti-itch patch includes a breathable layer, a drug isolation layer is attached to the side of the breathable layer near the release film, a drug layer is provided on the side of the drug isolation layer near the release film, and an adhesive layer is provided on the side of the drug layer near the release film.

[0006] Preferably, the cross-sections of the first and second tearable portions are arc-shaped, and the first and second tearable portions are the same size.

[0007] The above technical solution, through the design of easy-tear part one and easy-tear part two, makes it easy for users to tear the release film during use, saving operation time and making it highly practical.

[0008] Preferably, the diameter of the vent holes gradually increases from the inside to the outside, and multiple identical vent holes are provided, with the multiple vent holes distributed at equal intervals.

[0009] The above technical solution, through the design of breathable holes, avoids the accumulation of sweat between the anti-itch patch and the skin, reducing the probability of skin redness, swelling, and increased itching due to stuffiness and heat. It is especially suitable for long-term use. The design of multiple breathable holes further improves the overall breathability.

[0010] Preferably, the breathable layer is made of perforated nonwoven fabric, and the thickness of the breathable layer is 0.1mm to 1mm.

[0011] Through the above technical solution, the breathable layer made of mesh non-woven fabric has good breathability and moisture absorption, which can further improve the overall breathability of the anti-itch patch. Moreover, the mesh non-woven fabric is soft and gentle to the touch when in contact with the skin, and will not irritate sensitive skin, making it suitable for long-term use by dermatologists.

[0012] Preferably, the drug isolation layer is made of cellulose nanofiber material, and the thickness of the drug isolation layer is 0.01mm to 0.05mm.

[0013] Through the above technical solution, the drug isolation layer made of cellulose nanofiber material has excellent barrier properties, which can effectively isolate external dust, bacteria and other pollutants, prevent them from contacting the drug layer and causing drug contamination, and ensure the safety of drug use. At the same time, the drug isolation layer made of cellulose nanofiber material is biodegradable and has good air permeability.

[0014] Preferably, the adhesive layer is made of silicone pressure-sensitive adhesive, and the thickness of the adhesive layer is 50um~60um.

[0015] The adhesive layer made of silicone pressure-sensitive adhesive using the above technical solution has excellent adhesion, allowing the anti-itch patch to adhere firmly to the skin surface. It is not easy to fall off even when the patient is active, avoiding the inability of the drug to work continuously due to poor adhesion. At the same time, silicone pressure-sensitive adhesive has extremely low skin irritation and a low incidence of allergic reactions, making it suitable for dermatologists with sensitive skin and reducing skin problems caused by adhesive allergies.

[0016] Preferably, the release film is made of polyethylene and has a thickness of 25µm to 50µm.

[0017] Through the above technical solution, the release film made of polyethylene material has good barrier properties and chemical stability, which can effectively isolate external moisture, oxygen, dust and other substances, protect the drug layer inside the antipruritic patch from deterioration and moisture during storage, extend the product shelf life, and ensure that the efficacy of the drug is not affected during clinical use. At the same time, the surface of polyethylene material is smooth, adheres tightly to the adhesive layer but is easy to peel off, and the release film can be easily torn off during use without damaging the adhesive layer structure.

[0018] Compared with the prior art, this utility model provides an antipruritic device for clinical use in dermatology, which has the following beneficial effects: 1. This dermatological clinical anti-itch device features two easy-tear sections, making it convenient for users to tear the release film during use, saving operation time and increasing its practicality. The breathable design prevents sweat from accumulating between the patch and the skin, reducing the probability of skin redness, swelling, and increased itching due to heat and humidity. It is especially suitable for long-term use. Multiple breathable holes further enhance overall breathability. The breathable layer made of mesh non-woven fabric has excellent breathability and moisture absorption, further improving the overall breathability of the anti-itch patch. The soft mesh non-woven fabric feels gentle on the skin and will not irritate sensitive skin, making it suitable for long-term use by dermatologists. The drug isolation layer made of cellulose nanofiber material has excellent barrier properties, effectively isolating external dust, bacteria, and other contaminants to prevent contamination of the drug layer and ensuring drug safety. The drug isolation layer made of cellulose nanofiber material is also biodegradable and breathable. 2. This dermatological clinical antipruritic device uses a silicone-based pressure-sensitive adhesive layer with excellent adhesion, ensuring the antipruritic patch adheres firmly to the skin surface. It is not easily dislodged even during patient activity, preventing the medication from failing to maintain its effectiveness due to poor adhesion. Simultaneously, the silicone-based pressure-sensitive adhesive has extremely low skin irritation and a low incidence of allergic reactions, making it suitable for dermatologists with sensitive skin and reducing skin problems caused by adhesive allergies. The release film, made of polyethylene, has good barrier properties and chemical stability, effectively isolating external moisture, oxygen, dust, etc., protecting the medication layer inside the antipruritic patch from deterioration and moisture absorption during storage, extending the product's shelf life, and ensuring that the drug's efficacy is not affected during clinical use. Furthermore, the smooth surface of the polyethylene material adheres tightly to the adhesive layer but is easily peeled off, allowing for easy removal of the release film without damaging the adhesive layer structure. Attached Figure Description

[0019] Figure 1 This is a three-dimensional structural diagram of the present invention; Figure 2 This is a schematic diagram of the disassembled structure of this utility model; Figure 3 This is a schematic diagram of a half-section of the anti-itch patch of this utility model; Figure 4 This is a schematic diagram of the disassembled structure of the anti-itch patch of this utility model. Figure 1 ; Figure 5 This is a schematic diagram of the disassembled structure of the anti-itch patch of this utility model. Figure 2 .

[0020] The components are: 1. Anti-itch patch; 101. Breathable layer; 102. Drug isolation layer; 103. Drug layer; 104. Adhesive layer; 2. Release film; 3. Easy-tear part one; 4. Easy-tear part two; 5. Breathing holes. Detailed Implementation

[0021] The technical solutions of the present utility model will be clearly and completely described below with reference to the accompanying drawings of the embodiments. Obviously, the described embodiments are only some embodiments of the present utility model, and not all embodiments. Based on the embodiments of the present utility model, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the protection scope of the present utility model.

[0022] Example 1: As Figure 1-5 As shown, the present invention provides a dermatological clinical anti-itch device, including an anti-itch patch 1 and a release film 2. An easy-tear part 3 is fixedly installed on the outer edge of the release film 2, and an easy-tear part 4 is fixedly installed on the outer edge of the anti-itch patch 1. A vent hole 5 is opened on the side of the anti-itch patch 1 away from the release film 2. The anti-itch patch 1 includes a breathable layer 101, a drug isolation layer 102 is attached to the side of the breathable layer 101 near the release film 2, a drug layer 103 is provided on the side of the drug isolation layer 102 near the release film 2, and an adhesive layer 104 is provided on the side of the drug layer 103 near the release film 2.

[0023] Specifically, the cross-sections of easy-tear part 3 and easy-tear part 4 are arc-shaped, and easy-tear part 3 and easy-tear part 4 are the same size.

[0024] The advantage is that, through the design of easy-tear part 3 and easy-tear part 4, it is easy for users to tear the release film 2 during use, saving operation time and making it highly practical.

[0025] Specifically, the diameter of the vent 5 gradually increases from the inside to the outside, and multiple vent 5 are provided, with the multiple vent 5 distributed at equal intervals.

[0026] The advantage is that the design of the breathable holes 5 prevents sweat from accumulating between the anti-itch patch 1 and the skin, reducing the probability of skin redness, swelling, and increased itching due to stuffiness. It is especially suitable for long-term use. The design of multiple breathable holes 5 further improves the overall breathability.

[0027] Specifically, the breathable layer 101 is made of mesh nonwoven fabric, and the thickness of the breathable layer 101 is 0.1mm to 1mm.

[0028] The advantages are that the breathable layer 101 made of mesh non-woven fabric has good breathability and moisture absorption, which can further improve the overall breathability of the anti-itch patch 1. In addition, the mesh non-woven fabric is soft and gentle to the touch when in contact with the skin, and will not irritate sensitive skin, making it suitable for long-term use by dermatologists.

[0029] Example 2: Figure 2-5 As shown, this is an improvement on the previous embodiment.

[0030] Specifically, the drug isolation layer 102 is made of cellulose nanofiber material, and its thickness is 0.01mm to 0.05mm. The advantages are that the drug isolation layer 102 made of cellulose nanofiber material has excellent barrier properties, effectively isolating external dust, bacteria, and other contaminants, preventing them from contacting the drug layer 103 and causing drug contamination, thus ensuring the safety of drug use. At the same time, the drug isolation layer 102 made of cellulose nanofiber material is biodegradable and has good air permeability.

[0031] Specifically, the adhesive layer 104 is made of silicone pressure-sensitive adhesive, and its thickness is 50µm~60µm. The advantages are that the silicone pressure-sensitive adhesive layer 104 has excellent adhesion, allowing the anti-itch patch 1 to adhere firmly to the skin surface. It is not easily detached even during patient activity, preventing the medication from failing to work continuously due to poor adhesion. At the same time, silicone pressure-sensitive adhesive has extremely low skin irritation and a low incidence of allergic reactions, making it suitable for dermatologists with sensitive skin and reducing skin problems caused by adhesive allergies.

[0032] Specifically, the release film 2 is made of polyethylene and has a thickness of 25µm to 50µm. The advantages are that the polyethylene release film 2 has good barrier properties and chemical stability, effectively isolating external moisture, oxygen, dust, etc., protecting the drug layer 103 inside the antipruritic patch 1 from deterioration and moisture absorption during storage, extending the product's shelf life, and ensuring that the drug's efficacy is not affected during clinical use. At the same time, the smooth surface of the polyethylene material adheres tightly to the adhesive layer 104 but is easy to peel off, allowing the release film 2 to be easily removed without damaging the structure of the adhesive layer 104.

[0033] Working Principle: During use, the easy-tear part 3 and easy-tear part 4 design facilitates the user's tearing of the release film 2, saving operation time and enhancing practicality. The design of the breathable holes 5 prevents sweat from accumulating between the anti-itch patch 1 and the skin, reducing the probability of skin redness, swelling, and increased itching due to heat and stuffiness, making it especially suitable for long-term use. The multiple breathable holes 5 further improve overall breathability. The breathable layer 101, made of mesh non-woven fabric, has excellent breathability and moisture absorption, further enhancing the overall breathability of the anti-itch patch 1. The mesh non-woven fabric is soft and gentle on the skin, causing no irritation to sensitive skin, making it suitable for long-term use by dermatologists. The drug isolation layer 102, made of cellulose nanofiber material, has excellent barrier properties, effectively isolating external dust, bacteria, and other contaminants, preventing them from contacting the drug layer 103 and causing drug contamination, thus ensuring the safety of drug use. Simultaneously, the use of cellulose... The drug isolation layer 102, made of nanofiber material, is biodegradable and breathable. The adhesive layer 104, made of silicone pressure-sensitive adhesive, has excellent adhesion, allowing the anti-itch patch 1 to adhere firmly to the skin surface. It is not easy to fall off even when the patient is active, avoiding the inability of the drug to continue to work due to poor adhesion. At the same time, silicone pressure-sensitive adhesive has extremely low skin irritation and a low incidence of allergic reactions, making it suitable for dermatologists with sensitive skin and reducing skin problems caused by adhesive allergies. The release film 2, made of polyethylene material, has good barrier properties and chemical stability, effectively isolating external moisture, oxygen, dust, etc., protecting the drug layer 103 inside the anti-itch patch 1 from deterioration and moisture absorption during storage, extending the product's shelf life, and ensuring that the drug's efficacy is not affected during clinical use. At the same time, the surface of polyethylene material is smooth, adheres tightly to the adhesive layer 104, but is easy to peel off. The release film 2 can be easily torn off during use without damaging the structure of the adhesive layer 104.

[0034] Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the present invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A dermatological clinical antipruritic device, comprising an antipruritic patch (1) and a release film (2), characterized in that: The release film (2) has an easy-tear part one (3) fixedly installed on its outer edge, and the anti-itch patch (1) has an easy-tear part two (4) fixedly installed on its outer edge. The anti-itch patch (1) has a vent hole (5) on the side away from the release film (2). The anti-itch patch (1) includes a breathable layer (101), a drug isolation layer (102) is attached to the side of the breathable layer (101) near the release film (2), a drug layer (103) is provided on the side of the drug isolation layer (102) near the release film (2), and an adhesive layer (104) is provided on the side of the drug layer (103) near the release film (2).

2. The antipruritic device for clinical use in dermatology according to claim 1, characterized in that: The cross-sections of the first tearable part (3) and the second tearable part (4) are in the shape of an "arc". The first tearable part (3) and the second tearable part (4) are the same size.

3. The antipruritic device for clinical use in dermatology according to claim 2, characterized in that: The diameter of the vent (5) gradually increases from the inside to the outside. Multiple vents (5) are provided, and the multiple vents (5) are distributed at equal intervals.

4. The antipruritic device for clinical use in dermatology according to claim 1, characterized in that: The breathable layer (101) is made of mesh nonwoven fabric, and the thickness of the breathable layer (101) is 0.1mm to 1mm.

5. The antipruritic device for clinical use in dermatology according to claim 1, characterized in that: The drug isolation layer (102) is made of cellulose nanofiber material, and the thickness of the drug isolation layer (102) is 0.01mm to 0.05mm.

6. The antipruritic device for clinical use in dermatology according to claim 1, characterized in that: The adhesive layer (104) is made of silicone pressure-sensitive adhesive, and the thickness of the adhesive layer (104) is 50um~60um.

7. The antipruritic device for clinical use in dermatology according to claim 1, characterized in that: The release film (2) is made of polyethylene and has a thickness of 25um to 50um.

Citation Information

Patent Citations

  • Skin itching relieving patch

    CN212788878U